Cargando…
Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss
The muscular dystrophy X-linked mouse (mdx) is the most commonly used preclinical model for Duchenne muscular dystrophy. Although disease progression in the mouse does not perfectly model the human disease, it shares many pathological features. Early characterizations of the model reported severe pa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560899/ https://www.ncbi.nlm.nih.gov/pubmed/33057110 http://dx.doi.org/10.1038/s41598-020-74192-9 |
_version_ | 1783595175592853504 |
---|---|
author | Massopust, Ryan T. Lee, Young il Pritchard, Anna L. Nguyen, Van-Khoa M. McCreedy, Dylan A. Thompson, Wesley J. |
author_facet | Massopust, Ryan T. Lee, Young il Pritchard, Anna L. Nguyen, Van-Khoa M. McCreedy, Dylan A. Thompson, Wesley J. |
author_sort | Massopust, Ryan T. |
collection | PubMed |
description | The muscular dystrophy X-linked mouse (mdx) is the most commonly used preclinical model for Duchenne muscular dystrophy. Although disease progression in the mouse does not perfectly model the human disease, it shares many pathological features. Early characterizations of the model reported severe pathology through early adulthood followed by disease stabilization. As a result, research in the mdx mouse has largely focused on early adulthood. The overarching goal of this study is to improve the understanding of the mdx mouse model by tracking pathological features of the disease throughout life. We performed a thorough characterization of myofiber pathology in mdx mice from 2 weeks to 2 years of age. We report that individual mdx muscle fibers undergo progressive hypertrophy that continues through the lifespan. Despite massive hypertrophy on the myofiber level, we report no hypertrophy on the muscle level. These seemingly contradictory findings are explained by previously underappreciated myofiber loss in mdx mice. We conclude that due to myofiber loss, in combination with the progressive nature of other pathological features, aged mdx muscle tissue provides reliable benchmarks for disease progression that may be valuable in testing the efficacy of therapeutics for Duchenne muscular dystrophy. |
format | Online Article Text |
id | pubmed-7560899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75608992020-10-19 Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss Massopust, Ryan T. Lee, Young il Pritchard, Anna L. Nguyen, Van-Khoa M. McCreedy, Dylan A. Thompson, Wesley J. Sci Rep Article The muscular dystrophy X-linked mouse (mdx) is the most commonly used preclinical model for Duchenne muscular dystrophy. Although disease progression in the mouse does not perfectly model the human disease, it shares many pathological features. Early characterizations of the model reported severe pathology through early adulthood followed by disease stabilization. As a result, research in the mdx mouse has largely focused on early adulthood. The overarching goal of this study is to improve the understanding of the mdx mouse model by tracking pathological features of the disease throughout life. We performed a thorough characterization of myofiber pathology in mdx mice from 2 weeks to 2 years of age. We report that individual mdx muscle fibers undergo progressive hypertrophy that continues through the lifespan. Despite massive hypertrophy on the myofiber level, we report no hypertrophy on the muscle level. These seemingly contradictory findings are explained by previously underappreciated myofiber loss in mdx mice. We conclude that due to myofiber loss, in combination with the progressive nature of other pathological features, aged mdx muscle tissue provides reliable benchmarks for disease progression that may be valuable in testing the efficacy of therapeutics for Duchenne muscular dystrophy. Nature Publishing Group UK 2020-10-14 /pmc/articles/PMC7560899/ /pubmed/33057110 http://dx.doi.org/10.1038/s41598-020-74192-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Massopust, Ryan T. Lee, Young il Pritchard, Anna L. Nguyen, Van-Khoa M. McCreedy, Dylan A. Thompson, Wesley J. Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss |
title | Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss |
title_full | Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss |
title_fullStr | Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss |
title_full_unstemmed | Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss |
title_short | Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss |
title_sort | lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560899/ https://www.ncbi.nlm.nih.gov/pubmed/33057110 http://dx.doi.org/10.1038/s41598-020-74192-9 |
work_keys_str_mv | AT massopustryant lifetimeanalysisofmdxskeletalmusclerevealsaprogressivepathologythatleadstomyofiberloss AT leeyoungil lifetimeanalysisofmdxskeletalmusclerevealsaprogressivepathologythatleadstomyofiberloss AT pritchardannal lifetimeanalysisofmdxskeletalmusclerevealsaprogressivepathologythatleadstomyofiberloss AT nguyenvankhoam lifetimeanalysisofmdxskeletalmusclerevealsaprogressivepathologythatleadstomyofiberloss AT mccreedydylana lifetimeanalysisofmdxskeletalmusclerevealsaprogressivepathologythatleadstomyofiberloss AT thompsonwesleyj lifetimeanalysisofmdxskeletalmusclerevealsaprogressivepathologythatleadstomyofiberloss |